This site is intended only for Australian Healthcare Professionals
Choose your country
By clicking a link below you are choosing to leave the BioMarin Australia website; the country chosen is responsible for the content on that website.

VOXZOGO® Resource Library

This resource library contains information for prescribers, including resources to support patients and their caregivers.


▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

VOXZOGO® (vosoritide) is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Click here to review the approved Product Information

Information For Prescribers

VOXZOGO® PBS Prescribing Codes

A Quick guide to the VOXZOGO® PBS authority prescribing codes

Request a copy

VOXZOGO® Dosing Calculator

Select the correct dose for your patient and learn how it is administered

Click to view

VOXZOGO® Dosing and Administration Guide

This guide will familiarise you with administration so you can help patients and caregivers feel comfortable with daily injections.

Click to download

Publications

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

The study was an open-label, phase 3 extension study aimed to evaluate the safety and efficacy of long-term treatment with vosoritide in children with achondroplasia. (Ravi et al, 2021)

Access via Pubmed

C-Type natriuretic peptide analogue therapy in children with achondroplasia

This multinational, Phase 2, dose-finding study with a following extension study evaluated the safety and side-effect profile of vosoritide in 35 children with achondroplasia. (Ravi et al, 2019)

Access via Pubmed

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

This pivotal trial to investigated the safety and efficacy of once-daily subcutaneous injections of vosoritide in children with achondroplasia, with the primary endpoint as the change from baseline in mean annualised growth velocity at 52 weeks in treated patients as compared with controls. (Ravi et al, 2020)

Access via Pubmed

Literature review and expert opinion on the impact of achondroplasia on medical complications and health‑related quality of life and expectations for long‑term impact of vosoritide: a modified Delphi study

This study explored the perceived impact of achondroplasia on medical complications, HRQoL, healthcare resource use and mortality, and potential modifying effects of vosoritide, based on published evidence and expert opinion. (Ravi et al, 2022)

Access via Pubmed

Patient/Caregiver Resources

VOXZOGO® Injection Video

Watch the this injection video for step-by-step instructions on how to prepare and administer VOXZOGO®.

VOXZOGO® Patient starter kit

Everything your patient needs to get started with VOXZOGO, contained within a cooler bag: sharps container, alcohol wipes, band-aids, laminated injection calendar and other useful information.

Click here to request kits

VOXZOGO® Patient Resource Flyer

This flyer describes the support and resources available for patients who have been prescribed VOXZOGO®

Request a copy

VOXZOGO® Patient Administration Guide

This brochure provides information for families on achondroplasia, how VOXZOGO® works, and how to prepare and administer daily injections and should be read in conjunction with the Consumer Medicine Information

Request a copy

VOXZOGO® helpline

To talk to a healthcare professional for help with injection technique call 1800 418 385 or email voxzogo@cpharm.com.au

myVOXZOGO App

myVOXZOGO App is designed to support caregivers and children who are being treated with VOXZOGO®. The app provides personalised tools and resources to suit your patients’ needs.

Contact Us

Please contact us for more information.

Products available in Australia

BRINEURA® (cerliponase alfa)

BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

KUVAN® (sapropterin dihydrochloride)

KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) in sapropterin-responsive adult and paediatric patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.

NAGLAZYME® (galsulfase (rch))

NAGLAZYME® is indicated as long term enzyme replacement therapy in patients with Mucopolysaccharidosis VI (MPS VI, Nacetylgalactosamine 4- sulfatase deficiency, Maroteaux-Lamy syndrome).

VIMIZIM® (elosulfase alfa (rch))

VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis type IVA, morquio A syndrome).

VOXZOGO® (vosoritide)

VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.